

BRAWN BIOTECH LIMITED
(Formerly Known as Brawn Pharmaceuticals Limited)
Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024

Tel No. 011-43538733 Fax: 011-23275208; Email: solution@brawnbiotech.com; website: www.brawnbiotech.com
CIN:L74899DL1985PLC022468

Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2016

(Rs. In Lacs)

PART I					
	Particulars	3 months ended	Preceding 3	Corresponding	Previous year
		30/06/2016	months ended	3 months ended	ended
		Unaudited	Audited	Unaudited	Audited
1	Income from operations				
	Net sales/ income from operations (Net of excise duty)	1,448.96	1,138.18	958.10	4,562.24
	Other operating Income	26.86	18.19	16.67	126.14
	Total income from operations (net)	1,475.82	1,156.37	974.77	4,688.38
2	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	1,266.50	959.27	812.71	3,998.86
	(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	7.05	16.61	19.84	53.24
	(d) Employee benefits expense	44.65	59.31	34.20	186.18
	(e) Depreciation and amortisation expenses	0.70	0.56	0.88	3.32
	(f) Other expenses	119.54	111.59	56.22	307.52
	Total expenses	1,438.45	1,147.34	923.85	4,549.12
3	Profit / (Loss) from operation before other income,finance costs and exceptional items (1-2)	37.37	9.03	50.92	139.26
4	Other income	0.55	0.97	0.39	0.80
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3±4)	37.92	10.00	51.31	140.06
6	Finance Cost	0.30	0.45	0.19	9.57
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5±6)	37.62	9.55	51.12	130.49
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7±8)	37.62	9.55	51.12	130.49
10	Tax expense	12.21	27.49	-	35.52
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	25.41	(17.94)	51.12	94.97
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit / (Loss) for the period (11±12)	25.41	(17.94)	51.12	94.97
14	Paid-up equity share capital (Face Value of the Share shall be indicated)	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	277.98	252.57	244.83	252.57
16 i	Earnings per share (before extraordinary items) (not annualised): in Rs.				
	(a) Basic	0.85	(0.60)	0.82	3.17
	(b) Diluted	0.85	(0.60)	0.82	3.17
16	Earnings per share (after extraordinary items) (not annualised): in Rs.				
ii	(a) Basic	0.85	(0.60)	0.82	3.17
	(b) Diluted	0.85	(0.60)	0.82	3.17

Notes:

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their Meeting held on 05 August,2016.
- An amount of Rs. 2,68,16,475/-, appearing under Non Current Assets of the Balance Sheet for the year ended 31.03.2016, is under long pending litigation and as per views of the Board of Directors a provision for Bad and Doubtful Debts can be considered for such amount in the current Financial Year.
- The Statutory Auditors have carried out a Limited Review of the Financial Results for the Quarter ended 30th June, 2016.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting.
- Figures of the previous periods have been re-grouped, wherever necessary, to conform to the current periods classification.

For and on behalf of the Board
For Brawn Biotech Limited

Dated: 05.08.2016
Place: New Delhi

Brij Raj Gupta
(Managing Director)